MedTrace Logo

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions

NCT00864058 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-08-17

No results posted yet for this study

Summary

To compare the relative bioavailability of gabapentin 400 mg capsules (Purepac) with that of NEURONTIN® 400 mg capsules (Parke-Davis) in healthy adult male subjects under fasting conditions

Conditions

  • Healthy

Interventions

DRUG

Gabapentin 400 mg capsules

A: Experimental Subjects received Actavis formulated products under fasting conditions

DRUG

NEURONTIN® 400 mg capsules

B: Active comparator Subjects received Parke-Davis's marketed product

Sponsors & Collaborators

  • Actavis Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Siler, M.D. · Cetero Research, San Antonio

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-01-31
Primary Completion
1998-01-31
Completion
1998-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00864058 on ClinicalTrials.gov